The specialty drug pipeline is robust with several new medications anticipated to gain approval in the coming years. Healthcare leaders need to be poised to have a deep understanding of the clinical benefits and harms relative to existing therapies, establish…

Philadelphia-based Fox Chase Cancer Center has opened a new oncology satellite pharmacy, tripling its capacity to prepare chemotherapy and intravenous medications.  The facility, unveiled at a press conference and ribbon-cutting June 13, is located in the lower level of the…

Sarepta Therapeutics has suspended shipments of its Duchenne muscular dystrophy gene therapy, Elevidys, to nonambulatory patients following a second reported death due to acute liver failure. The biotech company, based in Cambridge, Mass., also paused dosing in its Envision clinical…

Total prescription dispensing revenue at U.S. retail pharmacies hit $683 billion in 2024, marking a 9% increase from the previous year, according to a June 16 post from the Drug Channels Institute. The institute calculated estimated total prescription revenue for…

From extensive regulatory reforms to economic pressures reshaping pharmacy access and pricing, these are some of the most impactful pharmacy stories since the start of 2025.  340B program under pressure  The future of the 340B drug pricing program has become…

Researchers at Rutgers University-New Brunswick (N.J.) are questioning the FDA’s 2020 decision to place a safety warning on a common antiseizure medication.  Lamictal (lamotrigine), a GSK medicine approved to treat epilepsy and bipolar disorder, accounts for about 10% of all…

Iowa Gov. Kim Reynolds has signed Senate Bill 383 into law, imposing new regulations on pharmacy benefit managers.  Here are five notes:

On June 5, the American Society of Health-System Pharmacists honored 23 members as 2025 Fellows, including 19 who serve hospitals and health systems.  To be named a fellow, an ASHP member must commit to excellence in practice for at least…

The FDA has approved Merck’s Enflonsia, a monoclonal antibody designed to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants.  The approval is based on data from a phase 2b/3 trial, which showed a 60.5% reduction in…

The FDA has launched a pilot program using generative AI to help expedite the review of drug and device applications, part of a sweeping modernization effort by the agency.  The initiative, led by FDA Commissioner Marty Makary, MD, and Vinay…